Two complementary lenses on the biotechnology sector
| Criteria | LSCIBP (Products) → | LSCIBC (Clinical Trials) → |
|---|---|---|
| Bloomberg Ticker | LSCIBP | LSCIBC |
| Focus | Commercial-stage biotech with FDA-approved drug | Clinical-stage biotech with drug in Phase 1/2/3 |
| Primary Value Driver | Recurring product revenue, reimbursement visibility | Clinical trial data readouts, regulatory catalysts |
| Key Risk | Pricing/reimbursement pressure, patent cliffs | Binary clinical trial outcomes, regulatory rejection |
| Revenue Profile | Established, growing product revenue | Pre-revenue or early-revenue |
| Volatility | Moderate — anchored by product cash flows | Higher — driven by event catalysts |
| M&A Relevance | Acquirers seek proven revenue streams | Acquirers seek pipeline innovation |
| Components | 61 | 124 |
| Median Market Cap (as of 12/31/25) |
$4.3B | $1.4B |
| Weighting | Equal weight | Equal weight |
| Reconstitution | Semi-annual (June & December) | Semi-annual (June & December) |
| Calculation Agent | Indxx, Inc. | Indxx, Inc. |